ArticleDiabetology & metabolic syndrome2025
Serum RAC1 as a potential biomarker in the early stages of diabetic kidney disease.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salt and chronic kidney disease.Nature reviews. Nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPreclinical studies have suggested that Ras-related C3 botulinum toxin substrate 1 (RAC1) accelerates diabetic kidney disease (DKD) progression by triggering renal inflammation/fibrosis. Nevertheless, the clinical relevance of RAC1 with DKD is undefined. In this study, we aimed to investigate the association between circulating RAC1 levels and early DKD to evaluate its potential as a novel biomarker for early disease detection.
methodsA total of 150 participants were recruited. They were divided into three groups: the type-2 diabetes mellitus (T2DM) group, the early DKD group, and the healthy volunteers (HVs). We measured the circulating level of RAC1 with ELISAs. In addition, we measured levels of two indicators of inflammation (NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome, and interleukin (IL)-1β) and two serological indicators reflecting renal fibrosis (fibrillin 1 (FBN1) and matrix metalloproteinase-10 (MMP-10)).
resultsThe serum level of RAC1 was increased in individuals with early DKD. The serum level of RAC1 was positively correlated with urinary clinical biomarkers, including the urine albumin-to-creatinine ratio (UACR), urine microalbumin (UMA), and α1-microglobulin (α1-MG), but inversely associated with the estimated glomerular filtration rate (eGFR). Serum levels of RAC1, NLRP3, IL-1β, and MMP-10 were strongly inter-correlated in DKD patients. In addition, after correction for pertinent clinical features and the other four biomarkers, an increased risk of early DKD was linked to a higher serum RAC1 level. Analyses of receiver operating characteristic (ROC) curves revealed the area under the ROC curve of serum levels of RAC1, NLRP3, IL-1β, and MMP-10 for identifying early DKD to be 0.785, 0.728, 0.697, and 0.714, respectively.
conclusionsThe circulating RAC1 level was associated with early DKD and might be a biomarker for the early stages of DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.